WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 7, 1375-1402. Review Article ISSN 2277–

A COMPUTATIONAL FRAMEWORK FOR MODERN HERBAL DRUG DEVELOPMENT: "INTEGRATING ARTIFICIAL INTELLIGENCE WITH NANOCARRIER SYSTEMS FOR ENHANCED PROBIOTIC DELIVERY"

Dr. Sethuramani A.*[1], Umayambigai R.[2], Thillaisathana T.[2], Thangam V.[2], Thirupavai B.[2], Charumathi N.[2], Ganesh S.[3]

[1]Associate Professor, Department of Pharmacognosy, College of Pharmacy, Madurai Medical College, Madurai, Tamil Nadu, India.

[2]Under Graduate, College of Pharmacy, Madurai Medical College, Madurai, Tamil Nadu, India.

[3]Post Graduate, Department of Pharmacognosy, College of Pharmacy, Madurai Medical College, Madurai, Tamil Nadu, India.

Article Received on 05 March 2026,
Article Revised on 25 March 2026,
Article Published on 04 April 2026

https://doi.org/10.5281/zenodo.19413341

***Corresponding Author**

Dr. Sethuramani A.

Associate Professor, Department of Pharmacognosy, College of Pharmacy, Madurai Medical College, Madurai, Tamil Nadu, India.

How to cite this Article: Dr. Sethuramani A.*[1], Umayambigai R.[2], Thillaisathana T.[2], Thangam V.[2], Thirupavai B.[2], Charumathi N.[2], Ganesh S.[3] (2026). A Computational Framework for Modern Herbal Drug Development: "Integrating Artificial Intelligence with Nanocarrier Systems for Enhanced Probiotic Delivery". World Journal of Pharmaceutical Research, 15(7), 1375–1402.

ABSTRACT

Probiotics offer substantial therapeutic potential for gastrointestinal, metabolic, and immune-related disorders; however, their clinical efficacy is severely limited by poor survival in the gastrointestinal tract, with conventional formulations achieving less than 10% viability at the target site. Nanocarrier systems—including polymeric nanoparticles, lipid-based carriers, hydrogels and nanoemulsions—provide physical encapsulation that protects probiotics from gastric acid, bile salts and enzymatic degradation, enabling targeted colonic delivery and enhanced epithelial adhesion. Yet, the multivariate complexity of nanocarrier optimization renders traditional trial-and-error development approaches impractical. This article presents a comprehensive framework for integrating artificial intelligence (AI) with probiotic nanocarrier systems. Machine learning algorithms, including XGBoost, artificial neural networks (ANNs), and reinforcement learning models, are

applied across the development pipeline: from strain–carriercompatibility screening and formulation optimization (reducing experimental runs by 60–80%) to long-term stability prediction and pharmacokinetic simulation. Disease-specific AI applications are explored for inflammatory bowel disease, irritable bowel syndrome, metabolic disorders, neurological conditions and dermatological diseases. Advanced applications including digital twin technology, federated learning for personalized probiotics and AI-driven nanosynbiotics design are discussed. Key limitations including data dependency, computational requirements, interpretability challenges and evolving regulatory frameworks are addressed alongside future directions in precision probiotic therapeutics.

KEYWORDS: probiotics, nanocarriers, artificial intelligence, machine learning, drug delivery, gastrointestinal targeting, precision medicine, nanosynbiotics.

1. INTRODUCTION

Probiotics, defined as **"live microorganisms that, when administered in adequate amounts, confer a health benefit on the host"** ***(FAO/WHO, 2001)***, represent a paradigm shift in therapeutic approaches for gastrointestinal disorders, immune modulation and metabolic health. The global probiotic market, valued at $58.17 billion in 2021, is projected to reach $105.6 billion by 2030, reflecting increasing recognition of their health benefits ***(Grand View Research, 2022)***. These benefits include restoration of gut microbiota balance, enhancement of intestinal barrier function, competitive exclusion of pathogens and modulation of systemic immune responses ***(Sanders et al., 2019).*** However, the therapeutic potential of probiotics is severely limited by delivery challenges. Conventional formulations including yogurts, capsules, and powders - offer minimal protection against the harsh gastrointestinal environment, resulting in survival rates typically below 10% ***(Cook et al., 2012).*** This inefficiency necessitates administration of high doses (10^9-10^{11} CFU) to ensure therapeutic efficacy, increasing costs and potential side effects.

Nanocarrier systems have emerged as promising solutions, providing physical encapsulation that shields probiotics from gastric acid, bile salts, and enzymatic degradation (***Yao et al., 2020)***. These systems enable targeted colonic delivery, controlled release, and enhanced epithelial adhesion. Yet, **nanocarrier design involves complex multivariate optimization that traditional trial-and-error approaches** cannot efficiently navigate. Artificial intelligence offers transformative potential in this context. By integrating machine learning algorithms with formulation science, AI enables predictive modeling, data-driven design, and

personalized optimization of probiotic nanocarriers ***(Paul et al., 2021)***. This article presents a comprehensive framework for AI-enhanced nanocarrier systems, demonstrating how intelligent optimization can overcome traditional limitations and enable precision probiotic therapeutics.

2. PROBIOTICS: MECHANISM & DELIVERY CHALLENGES

2.1 Mechanism of Action

Probiotics exert therapeutic effects through multiple, often synergistic mechanisms. Competitive exclusion involves competition with pathogens for adhesion sites and nutrients, creating a hostile environment through acid and bacteriocin production ***(O'Toole & Cooney, 2008).*** Barrier function enhancement occurs through upregulation of tight junction proteins (occludin, ZO-1) and increased mucus production ***(Ulluwishewa et al., 2011)***. Immune modulation includes induction of regulatory T-cells (Tregs), reduction of pro-inflammatory cytokines (TNF-α, IL-6), and stimulation of anti-inflammatory cytokines (IL-10) (Hardy et al., 2013). Metabolic contributions encompass production of short-chain fatty acids (SCFAs), vitamins (B12, K), and neurotransmitter precursors ***(Hill et al., 2014).***

2.2 Gastrointestinal Barriers

The oral route subjects probiotics to sequential, increasingly hostile environments.

Gastric Phase (pH 1-3, 2-4 hours): Hydrochloric acid (0.1-0.5 M) denatures proteins and disrupts cellular membranes, while pepsin catalyzes proteolytic degradation. Studies demonstrate 90-99% mortality of unprotected Lactobacillus and Bifidobacterium strains within 90 minutes of gastric exposure ***(Anal & Singh et al., 2007).***

Intestinal Phase (pH 6-7, 3-6 hours): Bile salts (0.2-2% concentration) act as biological detergents, solubilizing lipid membranes through micelle formation ***(Begley et al., 2005)***. Pancreatic enzymes (lipases, proteases, nucleases) further degrade cellular components. Rapid transit times (3-6 hours) limit colonization opportunities.

Colonic Phase (pH 7-8, 12-48 hours): Probiotics must compete with approximately 10^{13} CFU/g of resident microbiota for nutrients and adhesion sites ***(Sender et al., 2016)***. The mucus layer presents a physical barrier, while host immune surveillance may eliminate perceived invaders.

Cumulative Effect: Without protection, less than 10% of administered probiotics reach the colon in viable form ***(Frakolaki et al., 2021)***. This inefficiency necessitates delivery systems that provide sequential protection, targeted release, and facilitated colonization.

3. NANOCARRIER SYSTEMS FOR PROBIOTIC DELIVERY (CORE)

3.1 Conceptual Framework

Nanoencapsulation involves entrapping probiotic cells within nanometer-scale carriers (typically 50-500 nm). This approach provides multiple advantages: increased surface area for epithelial interactions, enhanced stability, controlled release kinetics, and potential for surface functionalization ***(McClements et al., 2018)***.

3.2 Classification and Characteristics

Polymeric Nanoparticles (50-500 nm): Formed from natural or synthetic polymers through techniques including ionotropic gelation, solvent evaporation, and nanoprecipitation. Chitosan-alginate complexes represent the most extensively studied system, offering pH-dependent release through protonation/deprotonation of amine groups ***(Zhang et al., 2022).***

Lipid-Based Systems (100-500 nm): Include liposomes (phospholipid bilayers enclosing aqueous cores) and solid lipid nanoparticles (solid lipid matrices). Liposomes offer excellent biocompatibility and can be surface-modified with targeting ligands, though stability during storage remains challenging ***(Liu et al., 2021).***

Hydrogels/Nanogels (100-1000 nm): Three-dimensional crosslinked polymer networks that swell in aqueous environments. Stimuli-responsive hydrogels release probiotics in response to pH changes (carboxylic acid-containing polymers), enzymes (peptide crosslinks), or temperature (poly(N-isopropylacrylamide)) ***(Oh et al., 2008)***.

Nanoemulsions (50-200 nm): Oil-in-water dispersions stabilized by surfactants. Probiotics partition into the hydrophobic oil phase, protected from aqueous stressors. High-pressure homogenization or ultrasonication creates fine droplets with enhanced stability (***Shima et al., (2006).***



Figure 1: Overview of nanocarrier systems for probiotic delivery, illustrating the key carrier types.

3.2 Material Selection

Natural Polymers

Chitosan: Cationic polysaccharide with mucoadhesive properties (amine groups interact with negatively charged mucin)

Alginate: Anionic co-polymer forming ionotropic gels with calcium ions

Gelatin: Derived from collagen, offers thermal reversibility

Dextran: Bacterially synthesized, highly water-soluble

Lipid Components

Phospholipids: Soy or egg phosphatidylcholine for membrane formation

Triglycerides: Medium-chain for enhanced digestibility

Surfactants: Tween 80, Span 80 for emulsion stabilization

3.3 Protection and Release Mechanism

Physical Barrier: Polymer matrices or lipid bilayers prevent direct contact with stressors.

Microenvironment Creation: Carriers maintain optimal pH, oxygen tension, and nutrient availability.

Controlled Release

- Diffusion-controlled: Probiotics diffuse through polymer matrix pores
- Degradation-controlled: Polymer hydrolysis or enzymatic cleavage triggers release
- Stimuli-responsive: pH, temperature, or enzyme triggers cause carrier dissolution

Targeting Strategies

- Passive: Size-dependent accumulation (Enhanced Permeability and Retention effect)
- Active: Surface ligands (lectins, antibodies, peptides) bind specific receptors
- Magnetic: Iron oxide nanoparticles enable external magnetic guidance

3.4 Advantages Over Conventional Systems

Comparative studies demonstrate nanocarriers increase probiotic survival from <10% to >90%, extend shelf-life by 3-6 months, reduce required doses by 50-80%, and enable targeted delivery to specific intestinal regions ***(Wang et al., 2021)***.

Table 1: C*onventional probiotic systems advanced probiotic nanocarrier system*.

Features/ aspect	Conventional Probiotic Systems (Capsules, Foods)	Advanced Probiotic Nanocarrier Systems
Core Structure & Protection	Simple matrix or direct suspension; minimal to no engineered protection from gastric acid.	Engineered nanostructures (liposomes, polymer nanoparticles, nanoemulsions) that physically encapsulate and shield probiotics.
GI survival & visibility	**Low survival (<10%)**; high viability loss in stomach (pH 1-3) and small intestine due to bile salts.	**High survival (>90%)**; nanostructures provide a barrier against harsh GI conditions, drastically improving viable cell delivery.
Targeting & releasing mechanism	Non-specific; release depends on capsule dissolution, often starting in the stomach. No targeting.	**Smart, targeted release**; can be designed for **colon-specific delivery** using pH-sensitive, enzyme-sensitive, or time-dependent polymers.
Therapeutic applications & precision	Primarily for **general gut health maintenance**; inconsistent dosing at disease sites limits therapeutic use.	Enables **targeted therapy for specific diseases** (e.g., IBD, cancer); allows co-delivery with drugs/prebiotics (synbiotics) for enhanced efficacy.
Clinical evidence & outcomes	Effects can be variable; limited ability to deliver sufficient viable cells to specific inflamed or diseased tissues.	Growing evidence from preclinical/clinical studies shows improved outcomes in **ulcerative colitis remission** and reduced **chemotherapy side effects** like mucositis.

4. NEED FOR ADVANCED & INTELLIGENT OPTIMIZATION IN PROBIOTIC NANOCARRIERS

Traditional nanocarrier development relies on empirical, trial-and-error approaches with significant limitations.

4.1 Multivariate Complexity

Probiotic nanocarrier optimization involves simultaneous consideration of numerous variables.

Probiotic characteristics: Strain, size, membrane composition, metabolic requirements.
Carrier properties: Material composition, molecular weight, cross linking density, surface charge.

Process parameters: Homogenization speed, temperature, solvent ratios, drying methods.
Environmental factors: pH, ionic strength, enzymatic activity, microbiota composition.
Full factorial exploration of these variables would require thousands of experiments, making traditional approaches impractical and resource-intensive ***(Singh et al., 2020).***

4.2 Scale-up Challenges

Laboratory-scale success often fails to translate to industrial production due to

- Batch to batch variability in polymer sourcing and probiotic cultivation
- Process parameter sensitivity during scale-up (mixing efficiency, heat transfer)
- Equipment differences between laboratory and production scales
- Cost constraints that limit material choices and process complexity ***(Simon et al., 2015).***

4.3 Stability and Performance Prediction

Accelerated stability testing provides limited insight into long-term performance. Traditional models often fail to account for

- Non-linear degradation kinetics under varying storage conditions
- Synergistic stressor effects (temperature + humidity + oxygen)
- In vivo variability in gastrointestinal conditions between individuals
- Microbiome interactions that influence probiotic survival and activity ***(Waterman & Adami et al., 2005)***

These challenges necessitate the integration of artificial intelligence-based tools that can efficiently navigate complex design spaces, predict long-term performance and enable personalized optimization.

5. OVERVIEW OF ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL SCIENCES

Artificial intelligence represents a paradigm shift in pharmaceutical research, transitioning from empirical approaches to data-driven, predictive science. AI encompasses machine learning (ML), deep learning (DL), natural language processing, and computer vision, each offering unique capabilities for formulation optimization ***(Vamathevan et al., 2019).***

5.1 Core Concepts

Machine Learning: Algorithms that identify patterns in data without explicit programming. Supervised learning (regression, classification) uses labeled datasets, while unsupervised learning (clustering, dimensionality reduction) identifies inherent structures ***(Hastie et al., 2009).***

Deep Learning: Multi-layered neural networks that automatically extract hierarchical features from raw data. Convolutional neural networks (CNNs) excel at image analysis, while recurrent neural networks (RNNs) process sequential data ***(LeCun et al., 2015)***.

Reinforcement Learning: Agents learn optimal actions through environmental interaction and reward feedback, particularly valuable for dynamic optimization problems ***(Sutton & Barto et al., 2018).***

5.2 Pharmaceutical Applications

AI applications span the drug development pipeline

- Drug Discovery: Virtual screening, de novo molecular design, toxicity prediction.
- Formulation Development: Excipient selection, stability prediction, release modeling.
- Clinical Trials: Patient stratification, dose optimization, adverse event prediction.
- Manufacturing: Process monitoring, quality control, supply chain optimization ***(Schneider et al., 2018).***

5.3 Relevance to Nanotechnology

Nanocarrier design involves multivariate optimization of composition, structure, and process parameters. AI algorithms efficiently navigate this complex design space, predicting formulation-performance relationships and identifying optimal combinations ***(Bannigan et al., 2021).***

6. AI METHODOLOGY FOR PROBIOTIC NANOCARRIER

6.1 DATA SOURCES & PREPROCESSING

AI models for probiotic nanocarrier design draw from four database categories

I. Genomic Databases - Provide gut microbial genome sequences for training probiotic strain classification and personalized recommendation models. UHGG (204,938 gut genomes), NCBI RefSeq, HMP, and IMG/M supply training data for strain classification, genomic feature extraction and personalized probiotic recommendation models.

II. Nanoparticle Databases - Supply physicochemical and toxicity data for ML-based nanocarrier safety and formulation prediction. eNanoMapper, PubVINAS (705 nanomaterials, 2,142 descriptors), NanoCommons / NanoReg2 and caNanoLab (NCI) provide physicochemical and toxicity data for nanoQSAR and safety prediction models.

III. Clinical/Microbiome Databases - Link microbiome composition to disease outcomes for therapeutic response and strain selection modeling. MicrobiomeDB, GMrepo (86 phenotypes), ENA (146,583+ datasets) and ABIOME link microbiome composition to health outcomes for therapeutic performance prediction.

IV. Preprocessing — Addresses heterogeneity, class imbalance, missing data and leakage to ensure clean, unbiased model training.

- Inter-study heterogeneity → normalization and batch correction
- Class imbalance → SMOTE or weighted loss functions
- Missing data → mean/model-based imputation
- Data leakage → strict train-test structural separation

6.2 Strain–Carrier Matching: Precision Pairing Through Machine Learning

Machine learning algorithms enable systematic matching of probiotic strains to optimal nanocarrier systems by analyzing large biological datasets encompassing genomic, proteomic and metabolomic profiles. The XGBoost (Extreme Gradient Boosting) algorithm is particularly well-suited to this task due to its ability to handle high-dimensional biological data, manage missing values and provide feature importance rankings that reveal which strain characteristics most strongly influence carrier compatibility ***(FAO/WHO, 2001).***

Training data for strain–carrier matching models is typically sourced from published formulation studies with feature sets including probiotic cell dimensions (0.5–5 µm), membrane lipid composition, surface charge (zeta potential), stress tolerance indice and carrier physicochemical properties. A minimum dataset of 200 – 500 strain–carrier experimental pairs is recommended for reliable model performance ***(Pandey et al., 2023).***

The ProbML model, built on XGBoost, demonstrated 95.45% classification accuracy in identifying probiotic organisms from whole-genome sequences using 5-fold cross-validation on a dataset of 1,524 bacterial genomes***(Krishnan et al., 2025)***. Performance was evaluated using precision, recall, and F1-score to account for class imbalance between probiotic and non-probiotic strains.

Model validation approach

- **Cross-validation:** 5-fold stratified cross-validation to prevent data leakage.
- **Overfitting prevention:** L1/L2 regularization (alpha = 0.1, lambda = 1.0) and max tree depth constraints.
- **Performance metrics:** Accuracy, F1-score, AUC-ROC.
- **External validation:** Models should be tested on an independent holdout set (20% of data) not used during training.

Predictions prioritize strain–carrier combinations where cell wall rigidity and carrier porosity are compatible, eliminating unsuitable pairings before laboratory synthesis and reducing formulation screening costs by an estimated 40–60% (***Various Authors et al., 2025).***

➢ **How It Works**

Example (X–Y mapping)

Input X (features)

• Probiotic strain A

• Cell size = 1.2 µm

• Membrane lipid content = high

• Stress tolerance = strong

• Nanocarrier B

• Material = plant-based lipid

• Particle size = 120 nm

• Zeta potential = −18 mV

• Porosity = 0.65

Output Y (prediction)

• Compatibility = Yes

• Predicted survival probability = 92%

These AI systems perform compatibility assessments by correlating strain characteristics (X_1) with carrier properties (X_2) to predict interaction outcomes (Y).

Logical mapping used by the model

• If cell wall rigidity (X_1) + negative surface charge (X_2) → higher stability (Y↑)

• If fragile membrane (X_1) + high porosity (X_2) → lower survival (Y↓)

This computational screening step eliminates unsuitable combinations early, significantly reducing trial-and-error during formulation development.

6.3 Formulation Design: Intelligent Optimization of Delivery Systems

Once a compatible strain–carrier pair is identified, AI-driven Design of Experiments (DoE) simultaneously optimizes multiple formulation parameters rather than varying one factor at a time. Artificial Neural Networks (ANNs) are preferred over conventional Response Surface Methodology (RSM) alone because ANNs capture non-linear, high-order interactions between formulation variables that polynomial RSM models cannot represent (Agatonovic-Kustrin & Beresford (PMC)

Data requirements and preprocessing: Input features are normalized to a 0–1 scale to prevent dominance by high-magnitude variables (e.g., mixing speed in rpm versus polymer concentration in %). Datasets of 80–150 experimental runs, generated using a D-optimal or Latin Hypercube sampling design, are sufficient to train reliable ANN models for formulation optimization ***(Bhattacharjee et al., 2024).***

Architecture and training: A three-layer feed forward ANN (input layer → 1–2 hidden layers with 10–20 neurons → output layer) trained using back propagation with the Adam optimizer (learning rate = 0.001) achieves R^2 values of 0.92–0.98 for predicting particle size, zeta potential and encapsulation efficiency from formulation parameters (Li et al., 2015). Dropout regularization (rate = 0.2) prevents overfitting on small pharmaceutical datasets.

Validation approach

- **Cross-validation:** Leave-one-out cross-validation (LOOCV) is recommended for small datasets (<100 runs)
- **Performance metrics:** R^2 (coefficient of determination), RMSE (root mean square error) and mean absolute error (MAE)
- **Comparison with baseline:** ANN predictions should be benchmarked against conventional RSM models; reported improvements in prediction accuracy are 15–25% for non-linear response surfaces ***(Agatonovic-Kustrin & Beresford, 2000).***

When ANN is combined with RSM using a hybrid approach, experimental runs required for optimization reduce by 60–80% compared to full factorial designs, while maintaining prediction accuracy above 90% ***(Various Authors et al., 2025).***

➢ **How It Works**

Example (A–B–Y optimization)

Input variables (A, B, C)

- A = Polymer concentration (%)
- B = Mixing speed (rpm)
- C = Crosslinking time (minutes)

ANN learns

- Non-linear interaction between A × B × C

Optimized Output Y

- Particle size = 110 nm
- Zeta potential = −22 mV
- Encapsulation efficiency = 85%

Why ANN is necessary here

- RSM models simple curvature
- ANN captures complex, non-linear relationships

Example

- Increasing polymer concentration (A↑) improves encapsulation
- But only if mixing speed (B) is within an optimal range
- ANN learns this interaction automatically

This allows intelligent exploration of multi-dimensional formulation spaces that are infeasible using conventional experimental methods alone.

6.4 Performance Prediction: Forecasting Stability and Biological Behavior

Machine learning models trained on stability datasets predict long-term formulation performance from initial physicochemical characterization data, enabling a shift from reactive stability testing to proactive performance forecasting.

Training data sources: Stability prediction models are trained on datasets combining accelerated stability study results (40°C/75% RH, ICH Q1A guidelines) with real-time storage data. Publicly accessible repositories such as the Excipient and Formulation Database and literature-mined stability datasets provide foundational training data (***Hill et al., 2014).*** Feature sets typically include particle size, zeta potential, polydispersity index, moisture content, storage temperature, humidity and packaging material.

Published model performance: Random Forest and Gradient Boosting models trained on nanoparticle stability datasets achieve prediction accuracy of 85–92% for shelf-life classification (>12 months vs <12 months) using 10-fold cross-validation ***(Anal & Singh, 2007)***. Gaussian Process Regression models provide probabilistic predictions with confidence intervals, which is particularly valuable for regulatory submissions requiring uncertainty quantification ***(Begley et al., 2005).***

Validation approach

- **Internal validation:** 10-fold cross-validation with stratified sampling.
- **External validation:** Prospective testing on 3–5 independently formulated batches not included in the training set.
- **Performance metrics:** For regression tasks (shelf-life in months): R^2, RMSE, MAE. For classification tasks (stable/unstable): AUC-ROC, precision, recall.
- **Benchmark comparison:** Models should be compared against traditional Arrhenius equation predictions to quantify improvement.

Pharmacokinetic modeling integration: GastroPlus® (Simulations Plus) and PK-Sim® (open-source) integrate ML-predicted release parameters with compartmental pharmacokinetic models to simulate in vivo absorption (Sender et al., 2016). PK-Sim® is freely available at: https://github.com/Open-Systems-Pharmacology/PK-Sim.

Table 2: Predicted vs actual comparison (from published literature).

Parameter	Traditional Model Prediction Error	ML Model Prediction Error
Particle size after 6 months	±18%	±6%
Encapsulation efficiency retention	±22%	±8%
Shelf-life classification accuracy	71%	89%

Example (X → Y prediction)

Input X

- Particle size = 120 nm
- Zeta potential = −20 mV
- Storage temperature = 25 °C
- Humidity = 60%

Predicted Output Y

- Shelf life = 14 months
- Stability retention after 6 months = 90%

Reported prediction accuracy: >85%

Pharmacokinetic (PK) modeling integration

To complement ML predictions, pharmacokinetic simulation tools (e.g., GastroPlus®) model in-body behavior.

Example (A → B → Y)

- A = Formulation properties
- B = Simulated GI transit + release kinetics
- Y = Predicted absorption window and release duration

This enables virtual screening of candidates before synthesis, ensuring only the most promising systems proceed to experimental testing.

➢ **GASTRO PLUS AI**

GastroPlus AI is an advanced simulation platform that uses artificial intelligence to create digital models of the human gastrointestinal system, enabling virtual testing of probiotic nanocarriers by predicting their survival, release profiles, and therapeutic efficacy under diverse physiological conditions without requiring physical human trials.



Figure 2: Workflow diagram illustrating GastroPlus AI simulation of probiotic nanocarrier behavior across gastrointestinal compartments, predicting survival, release profiles, and therapeutic efficacy.

7. ANOTHER MILESTONE: HOW AI HELPS IN DISEASES TREATED BY PROBIOTIC NANOCARRIERS

AI transforms probiotics from general supplements to precision medicines by optimizing strain selection, delivery and personalization for specific diseases ***(Rajasekhar et al., 2023).***

➢ **Disease-Specific AI Optimization**

A. INFLAMMATORY BOWEL DISEASE (IBD) - Crohn's & Ulcerative Colitis

Problem: Inflammation in gut destroys probiotics; need targeted anti-inflammatory delivery.

AI Solution

• Strain Selection: AI identifies strains that produce IL-10 (anti-inflammatory)

• Delivery Design: AI designs pH/enzyme-sensitive nanocarriers that release ONLY in inflamed areas

• Personalization: AI matches strains to patient's microbiome profile.

Example: AI selects ***L. reuteri*** + designs alginate carrier → Reduces TNF-α by 80% ***(Liu et al., 2025).***

B. IRRITABLE BOWEL SYNDROME (IBS)

Problem: Different subtypes (diarrhea/constipation/mixed) need different probiotics.

AI Solution

• Subtype Matching: AI analyzes symptoms → Recommends specific strains

• Release Timing: AI designs time-release carriers for symptom patterns

• Diet Integration: AI combines with personalized dietary recommendations

Example: For IBS-D (diarrhea), AI chooses ***B. infantis*** + slow-release coating ***(Rajasekhar et al., 2023).***

C. OBESITY & METABOLIC DISORDERS

Problem: Need probiotics that alter metabolism and reduce fat absorption.

AI Solution

• Metabolic Engineering: AI designs probiotics that produce appetite-suppressing hormones

• Nanocarrier Design: AI creates bile-resistant carriers for small intestine targeting

• Microbiome Analysis: AI identifies which gut bacteria predict weight loss success

Example: AI-engineered ***L. gasseri*** produces GLP-1 → Reduces hunger + improves glucose ***(Liu et al., 2025).***

D. MENTAL HEALTH (Gut-Brain Axis)

Problem: Need probiotics that produce neurotransmitters and cross blood-brain barrier.

AI Solution

• Neurotransmitter Prediction: AI identifies strains producing serotonin/GABA

• Carrier Design: AI designs nanoparticles that help probiotics communicate with brain

• Stress Response: AI models which probiotics reduce cortisol best ***(Topol et al., 2019)***.

Example: AI-optimized *B. longum* + neural-targeted carrier → Reduces anxiety by 60% ***(Purohit et al., 2023).***

E. SKIN DISEASES (Eczema, Psoriasis)

Problem: Oral probiotics often don't reach skin effectively.

AI Solution

• Skin-Gut Axis Mapping: AI finds gut strains that reduce skin inflammation

• Transdermal Delivery: AI designs nanoparticles for topical application

• Immune Modulation: AI selects strains that balance Th1/Th2 immune response

Example: AI-formulated ***L. rhamnosus*** topical gel → Improves eczema by 75% ***(Liu et al., 2025).***

F. AUTOIMMUNE DISEASES

Problem: Need to modulate immune system without over-activation.

AI Solution

• Immune Profiling: AI analyzes patient's immune markers

• Precision Strains: AI selects strains that increase T-reg cells specifically

• Safety Screening: AI ensures no strain triggers autoimmune flare-ups

Example: AI-matched ***Faecalibacterium prausnitzii*** → Increases regulatory T-cells ***(Zmora et al., 2018).***

8. ADVANCED AI APPLICATIONS

8.1 AI for Probiotic Capacity Enhancement

- Machine learning analyzes multi-omics data to identify genetic modifications that enhance probiotic functionality. CRISPR guide RNA design algorithms predict optimal targets for inserting genes encoding therapeutic proteins (anti-inflammatory cytokines, antimicrobial peptides) or enhancing stress resistance ***(Hsu et al., 2014).***

- Metabolic engineering optimization uses flux balance analysis coupled with ML to redesign probiotic metabolic pathways for enhanced production of beneficial metabolites (SCFAs, vitamins, neurotransmitters) ***(O'Brien et al., 2015)***.

8.2 Precision and Personalized Probiotics

- Federated learning enables collaborative model training across multiple institutions while maintaining data privacy. These models predict individual responses to specific probiotic strains based on genomics, microbiome composition, and clinical history ***(Kairouz et al., 2021).***

• Digital twin technology creates virtual representations of patients' gastrointestinal systems, simulating probiotic colonization, metabolic activity, and therapeutic effects before administration ***(Viceconti et al., 2021).***

- **8.3 Postbiotics and Paraprobiotics**

▪ AI facilitates the transition from live probiotics to postbiotics (inactivated microbial cells) and paraprobiotics (cellular components with biological activity). Machine learning identifies

optimal inactivation methods (heat, UV, chemical) that preserve therapeutic components while ensuring safety ***(Aguilar-Toalá et al., 2018).***

- Computer vision analyzes microscopic images to quantify cellular integrity after inactivation, correlating morphological features with biological activity ***(Ronneberger et al., 2015).***

- **8.4 Nanosynbiotics and Engineered Probiotics**

Nanosynbiotics - nanocarriers co-encapsulating probiotics and prebiotics - are optimized through AI to achieve synchronized release and synergistic effects. Molecular docking simulations predict optimal prebiotic-probiotic combinations based on receptor affinity and metabolic compatibility ***(Morris et al., 2009)***.

- Engineered probiotics with reporter genes or therapeutic payloads are designed using generative adversarial networks that create novel genetic constructs optimized for specific functions (pathogen detection, drug production) ***(Goodfellow et al., 2014)***.

- **8.5 Industry and Market Perspective**

Natural language processing analyzes social media, scientific literature, and market reports to identify trends in probiotic consumer preferences, guiding product development ***(Liu et al., 2020).***

- Predictive analytics forecast market adoption based on clinical efficacy data, pricing models, and regulatory pathways, optimizing investment and development strategies ***(Choi et al., 2021).***

8. ADVANTAGES & LIMITATIONS ON INTEGRATING WITH AI

8.1 Advantages

Enhanced Efficacy: AI-optimized nanocarriers increase probiotic survival from <10% to >90%, improve colonic targeting from negligible to 70-80% and enhance therapeutic outcomes by 2-3 fold compared to conventional formulations ***(Mitchell et al., 2021).***

Accelerated Development: Formulation optimization timelines reduce from 12-18 months to 4-6 weeks through predictive modeling and intelligent DoE, with first-iteration success rates increasing from 20% to 85% ***(Bannigan et al., 2021).***

Cost Efficiency: Material requirements decrease by 60-70%, personnel time reduces by 80%, and batch failure rates drop from 30% to <5%, substantially lowering development and production costs ***(Paul et al., 2021)***.

Personalization Capability: AI enables patient-specific formulation based on individual physiology, microbiome, and disease state, moving beyond one-size-fits-all approaches ***(Zmora et al., 2018)***.

Continuous Improvement: Machine learning models continuously incorporate new experimental data, progressively improving prediction accuracy and formulation performance ***(Jordan & Mitchell et al., 2015***).

8.2 Limitations

Data Dependency: Model accuracy depends on training data quality and quantity. Limited datasets for novel materials or probiotic strains constrain predictive capability ***(Gundersen & Kjensmo et al., 2018***).

Computational Requirements: Complex simulations (molecular dynamics, pharmacokinetic modeling) demand high-performance computing resources, creating cost and accessibility barriers ***(Lee & Yoon, 2021).***

Interpretability Challenges: Deep learning models often function as "black boxes," providing accurate predictions without transparent reasoning, complicating regulatory approval ***(Rudin et al., 2019)***.

Regulatory Uncertainty: Guidelines for AI-designed biologics remain under development with evolving requirements for algorithm validation, data integrity and continuous learning systems ***(Gerke et al., 2020).***

Integration Complexity: Implementing AI workflows within existing pharmaceutical development pipelines requires significant infrastructure investment and interdisciplinary expertise ***(Bhavsar et al., 2022)***.

9. FUTURE SCOPES

- **Patient-Specific Probiotic Nanocarriers**

Future probiotics won't be "one-size-fits-all." AI will enable precision probiotics, where the strain and its protective nanocarrier are tailored to your unique biology.

How it works: By analyzing your personal health data, microbiome profile and genetic markers. AI models can predict which specific probiotic strain and delivery method will work best for your condition, whether it's IBD or IBS ***(Zmora et al., 2018; Rajasekhar et al., 2023).***

The Goal: To create truly personalized treatments, moving beyond general supplements to targeted "living medicines" designed for individual patients ***(Topol et al., 2019).***

- **AI-Driven Automated Formulation**

Instead of slow, manual lab work, AI will automatically design and optimize the best probiotic formulas. This uses a technique called active machine learning.

How it works: Scientists can train an AI with just a few experimental results (e.g., how six different materials affect a probiotic). The AI then predicts the effects of hundreds of other materials, dramatically speeding up the discovery of the perfect protective coating to help probiotics survive the gut ***(Burger et al., 2020***).

The Goal: To move from human-led experimentation to AI systems that continuously propose, test, and refine new probiotic-nanocarrier combinations for maximum survival and efficacy ***(Sanchez-Lengeling & Aspuru-Guzik et al., 2018***).

- **Digital Twins & Smart Manufacturing**

A "digital twin" is a real-time virtual copy of a physical manufacturing process. In the factory of the future, this will revolutionize how we produce nanocarriers.

How it works: Sensors in a bioreactor send live data (temperature, pH) to its digital twin. The AI model simulates and predicts outcomes, allowing engineers to run thousands of virtual experiments to find the perfect, reproducible "golden batch" settings before making anything real ***(Kaushik et al., 2022; Wang et al., 2022).***

The Goal: To ensure every batch of probiotic nanocarriers is consistently perfect, transitioning from risky, variable production to predictable, smart manufacturing ***(Viceconti et al., 2021).***

10. DISCUSSION

Through this comprehensive compendium, we elucidated that probiotics suffer critical viability attrition across the gastrointestinal milieu, wherein less than 10% of the administered microbial inoculum survives sequential physicochemical barriers including gastric acid-mediated proteolysis, bile salt-induced membrane solubilization, and pancreatic enzymatic hydrolysis ***(Krishnan et al., 2025; Frontend et al., 2021; MDPI Foods et al., 2025)***, thereby necessitating supraphysiological inoculation doses that render conventional formulations therapeutically inefficient. We comprehended that nanocarrier platforms — encompassing polymeric nanoparticles, liposomes, and stimuli-responsive hydrogels — can augment probiotic survivability beyond 90% through spatiotemporally controlled release ***(Scientific Reports et al., 2024; PMC et al., 2024)***, yet their optimization demands navigation of an extraordinarily high-dimensional parameter space that renders empirical methodologies wholly untenable, substantiating the imperative for AI integration.

We recognized that AI-driven tools including ProbML and XGBoost models achieve remarkable genomic screening accuracy, enabling rapid identification of novel probiotic strains and next-generation probiotics (NGPs) with specific therapeutic potentials ***(Krishnan et al., 2025; Venkatesh et al., 2022).*** Beyond strain discovery, we observed that predictive models systematically map complex interactions between microbial species, their therapeutic metabolites — encompassing paraprobiotics and postbiotics — and host health outcomes, thereby providing a mechanistic foundation for rational formulation design ***(ScienceDirect et al., 2025; MDPI Fermentation et al., 2025)***. We further recognized that ensemble machine learning architectures, RSM-ANN synergistic frameworks, and pharmacokinetic simulation platforms collectively transmute formulation science from reactive empiricism to proactive computational inference, curtailing experimental iterations by 60–80% while forecasting physicochemical stability with fidelity exceeding 85% ***(Nature Scientific Reports et al., 2025; ScienceDirect et al., 2023; ScienceDirect et al., 2025; PMC et al., 2025).***

We were particularly struck by the application of active ML and molecular docking approaches in optimizing nanocarrier delivery systems, wherein AI-predicted interactions between probiotics, excipients, and carrier materials facilitated the rational engineering of sophisticated Nanosynbiotics with enhanced bioavailability, stability, and spatially restricted gastrointestinal release ***(McCoubrey et al., 2022; PMC et al., 2024)***. This capacity extended meaningfully into disease-specific therapeutics, with demonstrated TNF-α attenuation in IBD,

anxiolytic efficacy via gut-brain axis modulation, and amelioration of atopic dermatitis — collectively repositioning probiotics from broad-spectrum supplementation to molecularly targeted, patient-stratified biotherapeutics ***(Science Advances et al., 2023; Krishnan et al., 2025; PMC et al., 2024; ScienceDirect et al., 2023)***. In summation, we concluded that despite tractable constraints including deep learning interpretability opacity and regulatory lacunae surrounding algorithmic validation, the convergence of artificial intelligence with nanocarrier-mediated delivery constitutes a definitive paradigm shift, engineering omics-informed, individually personalized living therapeutics with profound implications for the future of microbiome-targeted precision medicine ***(ScienceDirect et al., 2025).***

11. CONCLUSION

AI AS THE CATALYST FOR NEXT-GENERATION PROBIOTIC THERAPEUTICS

The capabilities elucidated across this compendium ultimately converge to enable true personalization, wherein AI models systematically analyze individual microbiome compositional data, dietary patterns, and host health markers to tailor probiotic and synbiotic interventions for patient-stratified conditions including IBS, IBD, and atopic dermatitis. This analytical capacity — spanning strain selection, nanocarrier formulation optimization, functional food production, and pharmaceutical market forecasting — collectively positions AI as an indispensable force multiplier that propels probiotic science beyond the limitations of conventional empirical approaches. Ensemble machine learning architectures, RSM-ANN synergistic frameworks, and molecular docking platforms transmute formulation science from reactive empiricism to proactive computational inference, while AI-driven genomic screening tools including ProbML and XGBoost models accelerate the identification of next-generation probiotics with precision therapeutic potentials. These converging capabilities reposition probiotics from broad-spectrum supplementation to dynamically engineered, precision-delivered, and individually matched biotherapeutics — solidifying their role as molecularly targeted agents in precision medicine. In summation, despite tractable constraints including deep learning interpretability opacity and regulatory lacunae surrounding algorithmic validation, the convergence of artificial intelligence with nanocarrier-mediated probiotic delivery constitutes a definitive paradigm shift, laying the foundation for omics-informed, personally tailored living therapeutics with profound and far-reaching implications for the future of microbiome-targeted precision medicine.

"AI - Serves As The Foundational Catalyst, Transforming Medicine From Generalized Treatment Into A Dynamic, Data-Driven Science Of Intelligent, Predictive And Personalized Healthcare."

REFERENCES

1. Additional reference: https://pubmed.ncbi.nlm.nih.gov/35150845/
2. Aguilar-Toalá, J. E., et al. (2018). Postbiotics: An evolving term within the functional foods field. Trends in Food Science & Technology. https://www.sciencedirect.com/science/article/abs/pii/S0924224417304077
3. AI-Driven Nanoarchitectonics (PubMed): https://pubmed.ncbi.nlm.nih.gov/40772340/
4. Anal, A. K., & Singh, H. (2007). Recent advances in microencapsulation of probiotics. Trends in Food Science & Technology. https://pubmed.ncbi.nlm.nih.gov/17257829/
5. Anderson, M. J., & Whitcomb, P. J. (2016). RSM Simplified: Optimizing Processes Using Response Surface Methods for Design of Experiments. Productivity Press. https://www.routledge.com/RSM-Simplified-Optimizing-Processes-Using-Response-Surface-Methods-for/Anderson-Whitcomb/p/book/9781498745475
6. Babic, B., et al. (2021). The algorithm audit: Scoring the algorithms that score us. Big Data & Society. https://journals.sagepub.com/doi/10.1177/20539517211038876
7. Bannigan, P., et al. (2021). Machine learning directed drug formulation development. Advanced Drug Delivery Reviews. https://pubmed.ncbi.nlm.nih.gov/33895300/
8. Bannigan, P., et al. (2021). Machine learning directed drug formulation development. Advanced Drug Delivery Reviews. https://pubmed.ncbi.nlm.nih.gov/33895300/
9. Begley, M., et al. (2005). The interaction between bacteria and bile. FEMS Microbiology Reviews. https://pubmed.ncbi.nlm.nih.gov/15837370/
10. Bhavsar, K. A., et al. (2022). Artificial intelligence in pharmaceutical technology. Drug Delivery and Translational Research. https://pubmed.ncbi.nlm.nih.gov/35622313/
11. Bradski, G. (2000). The OpenCV Library. Dr. Dobb's Journal of Software Tools. https://docs.opencv.org/
12. Burger, B., et al. (2020). A mobile robotic chemist. Nature. https://www.nature.com/articles/s41586-020-2442-2
13. Chen, Y., et al. (2021). Artificial neural networks for optimization of probiotic microencapsulation in alginate beads. Journal of Microencapsulation. https://pubmed.ncbi.nlm.nih.gov/32780662/

14. Choi, D. W., et al. (2021). Predictive analytics for pharmaceutical market forecasting. Drug Discovery Today. https://pubmed.ncbi.nlm.nih.gov/33774196/
15. COMSOL. (2021). COMSOL Multiphysics Reference Manual. https://www.comsol.com/documentation
16. Cook, M. T., et al. (2012). Microencapsulation of probiotics for gastrointestinal delivery. Journal of Controlled Release. https://pubmed.ncbi.nlm.nih.gov/22698940/
17. Devlin, J., et al. (2018). BERT: Pre-training of deep bidirectional transformers for language understanding. arXiv. https://arxiv.org/abs/1810.04805
18. Dunn, J., et al. (2018). Wearable sensors for personalized nutrition and exercise. Biosensors and Bioelectronics. https://pubmed.ncbi.nlm.nih.gov/29524902/
19. FAO/WHO. (2001). Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. https://openknowledge.fao.org/items/1c836817-9be2-4256-83ae-0b5055039b50
20. Frakolaki, G., et al. (2021). A review of the microencapsulation techniques for the incorporation of probiotic bacteria in functional foods. Critical Reviews in Food Science and Nutrition. https://pubmed.ncbi.nlm.nih.gov/32498569/
21. Gerke, S., et al. (2020). Ethical and legal challenges of artificial intelligence-driven healthcare. Artificial Intelligence in Healthcare. https://pmc.ncbi.nlm.nih.gov/articles/PMC7332220/
22. Goodfellow, I., et al. (2014). Generative adversarial nets. arXiv. https://arxiv.org/abs/1406.2661
23. Grand View Research. (2022). Probiotics Market Size, Share & Trends Analysis Report. https://www.grandviewresearch.com/industry-analysis/probiotics-market
24. Gundersen, O. E., & Kjensmo, S. (2018). State of the art: Reproducibility in artificial intelligence. AAAI Conference on Artificial Intelligence. https://ojs.aaai.org/index.php/AAAI/article/view/11503
25. Gupta, R., et al. (2022). ProbML: A machine learning approach for identification of probiotic organisms from whole genome sequences. Bioinformatics. https://pubmed.ncbi.nlm.nih.gov/35059524/
26. Hardy, H., et al. (2013). Probiotics, prebiotics and immunomodulation of gut mucosal defences. Frontiers in Immunology. https://pmc.ncbi.nlm.nih.gov/articles/PMC3798953/
27. Hastie, T., et al. (2009). The Elements of Statistical Learning. Springer. https://www.springer.com/gp/book/9780387848570

28. Hill, C., et al. (2014). Expert consensus document: The ISAPP consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology. https://pubmed.ncbi.nlm.nih.gov/24912386/
29. Hsu, P. D., et al. (2014). Development and applications of CRISPR-Cas9 for genome engineering. Cell. https://pubmed.ncbi.nlm.nih.gov/24906146/
30. Jamei, M., et al. (2009). The Simcyp population-based ADME simulator. Expert Opinion on Drug Metabolism & Toxicology. https://pubmed.ncbi.nlm.nih.gov/19671031/
31. Jordan, M. I., & Mitchell, T. M. (2015). Machine learning: Trends, perspectives, and prospects. Science. https://pubmed.ncbi.nlm.nih.gov/26185243/
32. Kairouz, P., et al. (2021). Advances and open problems in federated learning. Foundations and Trends in Machine Learning. https://arxiv.org/abs/1912.04977
33. Kaushik et al. (2022) – Pharma 4.0 AI Digital Twins: https://www.mdpi.com/1999-4923/14/10/2113
34. LeCun, Y., et al. (2015). Deep learning. Nature. https://www.nature.com/articles/nature14539
35. Lee, D., & Yoon, S. N. (2021). Application of artificial intelligence-based technologies in the healthcare industry. International Journal of Environmental Research and Public Health. https://pmc.ncbi.nlm.nih.gov/articles/PMC7967573/
36. Lee, J., et al. (2015). Service innovation and smart analytics for Industry 4.0 and big data environment. Procedia CIRP. https://www.sciencedirect.com/science/article/pii/S2212827114008877
37. Li, H., et al. (2022). Reinforcement learning for pH-responsive drug delivery system design. ACS Applied Materials & Interfaces. https://pubmed.ncbi.nlm.nih.gov/35195993/
38. Liao, W., et al. (2021). Machine learning for probiotic strain identification and characterization. Computational and Structural Biotechnology Journal. https://pubmed.ncbi.nlm.nih.gov/34527186/
39. Liu et al. (2025) – AI-Driven Nanoarchitectonics (Advanced Materials): https://advanced.onlinelibrary.wiley.com/doi/10.1002/adma.202510239
40. Liu, X., et al. (2020). Social media mining for drug safety signal detection. Journal of Biomedical Informatics. https://pubmed.ncbi.nlm.nih.gov/32247028/
41. Liu, Y., et al. (2021). Liposome-based delivery systems for probiotics. Journal of Agricultural and Food Chemistry. https://pubmed.ncbi.nlm.nih.gov/34351745/
42. MathWorks. (2021). MATLAB Version 9.10 (R2021a). https://www.mathworks.com/products/matlab.html

43. McClements, D. J. (2018). Encapsulation, protection, and delivery of bioactive proteins and peptides using nanoparticle and microparticle systems. Advances in Colloid and Interface Science. https://pubmed.ncbi.nlm.nih.gov/29273373/
44. Mitchell, M. J., et al. (2021). Engineering precision nanoparticles for drug delivery. Nature Reviews Drug Discovery. https://pubmed.ncbi.nlm.nih.gov/33277608/
45. Morris, G. M., et al. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry. https://pubmed.ncbi.nlm.nih.gov/19399780/
46. O'Brien, E. J., et al. (2015). Using genome-scale models to predict biological capabilities. Cell. https://pubmed.ncbi.nlm.nih.gov/26000479/
47. Oh, J. K., et al. (2008). The development of microgels/nanogels for drug delivery applications. Progress in Polymer Science. https://www.sciencedirect.com/science/article/abs/pii/S0079670008000142
48. O'Toole, P. W., & Cooney, J. C. (2008). Probiotic bacteria influence the composition and function of the intestinal microbiota. Interdisciplinary Perspectives on Infectious Diseases. https://pmc.ncbi.nlm.nih.gov/articles/PMC2575564/
49. Ozbolat, I. T., & Yu, Y. (2013). Bioprinting toward organ fabrication: challenges and future trends. IEEE Transactions on Biomedical Engineering. https://pubmed.ncbi.nlm.nih.gov/23143569/
50. Paul, D., et al. (2021). Artificial intelligence in drug discovery and development. Drug Discovery Today. https://pmc.ncbi.nlm.nih.gov/articles/PMC7577280/
51. Paul, D., et al. (2021). Artificial intelligence in drug discovery and development. Drug Discovery Today. https://pmc.ncbi.nlm.nih.gov/articles/PMC7577280/
52. Pedregosa, F., et al. (2011). Scikit-learn: Machine learning in Python. Journal of Machine Learning Research. https://jmlr.org/papers/v12/pedregosa11a.html
53. Purohit et al. (2023) – Biosensors for GI microbiota monitoring: https://pmc.ncbi.nlm.nih.gov/articles/PMC10196119/
54. Roggo, Y., et al. (2007). A review of near infrared spectroscopy and chemometrics in pharmaceutical technologies. Journal of Pharmaceutical and Biomedical Analysis. https://pubmed.ncbi.nlm.nih.gov/17889474/
55. Ronneberger, O., et al. (2015). U-Net: Convolutional networks for biomedical image segmentation. arXiv. https://arxiv.org/abs/1505.04597

56. Rudin, C. (2019). Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead. Nature Machine Intelligence. https://www.nature.com/articles/s42256-019-0048-x
57. Sanchez-Lengeling, B., & Aspuru-Guzik, A. (2018). Inverse molecular design using machine learning. Science. https://pubmed.ncbi.nlm.nih.gov/30115744/
58. Sanders, M. E., et al. (2019). Probiotics and prebiotics in intestinal health and disease. Nature Reviews Gastroenterology & Hepatology. https://pubmed.ncbi.nlm.nih.gov/31296969/
59. Schneider, G. (2018). Automating drug discovery. Nature Reviews Drug Discovery. https://pubmed.ncbi.nlm.nih.gov/29242537/
60. Schuhmacher, A., et al. (2016). The pharmaceutical industry in 2020: Reinventing R&D. Drug Discovery Today. https://pubmed.ncbi.nlm.nih.gov/27554954/
61. Sender, R., et al. (2016). Revised estimates for the number of human and bacteria cells in the body. PLOS Biology. https://pmc.ncbi.nlm.nih.gov/articles/PMC4991899/
62. Shah, R., et al. (2022). Bayesian optimization for pharmaceutical formulation development. AAPS PharmSciTech. https://pubmed.ncbi.nlm.nih.gov/35091821/
63. Shima, M., et al. (2006). Protection of Lactobacillus acidophilus from bile salts in a model intestinal juice by incorporation into the inner-water phase of a W/O/W emulsion. Food Hydrocolloids. https://www.sciencedirect.com/science/article/abs/pii/S0268005X05001025
64. Simon, L. L., et al. (2015). Assessment of recent process analytical technology (PAT) trends. Organic Process Research & Development. https://pubs.acs.org/doi/10.1021/op500261y
65. Singh, B., et al. (2020). Artificial intelligence and machine learning in pharmaceutical development. Drug Development and Industrial Pharmacy. https://pubmed.ncbi.nlm.nih.gov/32536255/
66. Sutton, R. S., & Barto, A. G. (2018). Reinforcement Learning: An Introduction. MIT Press. http://incompleteideas.net/book/the-book-2nd.html
67. Team, R. C. (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing. https://www.r-project.org/
68. Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature Medicine. https://pubmed.ncbi.nlm.nih.gov/30617339/

69. Ulluwishewa, D., et al. (2011). Regulation of tight junction permeability by intestinal bacteria and dietary components. Journal of Nutrition. https://pubmed.ncbi.nlm.nih.gov/21084688/
70. Vamathevan, J., et al. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery. https://pubmed.ncbi.nlm.nih.gov/30976107/
71. Viceconti, M., et al. (2021). In silico trials: Verification, validation and uncertainty quantification of predictive models. Methods. https://pubmed.ncbi.nlm.nih.gov/33148506/
72. Wang, H., et al. (2022). Digital twin technology for personalized medicine. Nature Computational Science. https://www.nature.com/articles/s43588-022-00369-x
73. Wang, J., et al. (2021). Challenges and opportunities in the development of probiotic formulations. Food Bioscience. https://pubmed.ncbi.nlm.nih.gov/33823309/
74. Wang, Y., et al. (2021). Deep learning for predicting drug release from polymeric nanoparticles. Journal of Controlled Release. https://pubmed.ncbi.nlm.nih.gov/33737157/
75. Waterman, K. C., & Adami, R. C. (2005). Accelerated aging: prediction of chemical stability of pharmaceuticals. International Journal of Pharmaceutics. https://pubmed.ncbi.nlm.nih.gov/15694548/
76. Yao, M., et al. (2020). Nanocarriers for improving the stability and controlled release of probiotics. Current Pharmaceutical Design. https://www.sciencedirect.com/science/article/abs/pii/S0268005X21002988
77. Zhang, J., et al. (2020). Machine learning-assisted design of biomaterials for drug delivery. Biomaterials Science. https://pubmed.ncbi.nlm.nih.gov/32929434/
78. Zhang, Z., et al. (2022). Chitosan/alginate nanoparticles for oral delivery of probiotics. Carbohydrate Polymers. https://pubmed.ncbi.nlm.nih.gov/34800217/
79. Zmora, N., et al. (2018). Personalized gut mucosal colonization resistance to empiric probiotics. Cell. https://pubmed.ncbi.nlm.nih.gov/30193112/